The clearest answer yet to the question “How much exercise moves the needle on liver fat?” arrived in a 2026 Bayesian network meta-analysis in the Journal of Sport and Health Science. The authors pooled 24 randomized controlled trials with 961 participants and did something the field has avoided: they turned exercise into a dose, measured in MET-minutes per week, and then drew a dose-response curve with real clinical thresholds on it.
Three numbers anchor the whole analysis. The minimum clinically effective dose sits at 460 MET-minutes per week, the cost-effective optimum at 630, and the plateau, where extra volume stops buying extra liver benefit, at 850. Below 460 the trials mostly show noise; above 850 the curve flattens, which is the first honest “enough is enough” marker this literature has offered.
The type question got a sharper answer than before. Every exercise category, aerobic, resistance, combined, high-intensity interval, lowered hepatic steatosis significantly. But when ranked head to head, aerobic plus resistance training beat the others on both effect size and dose efficiency, with an optimal prescription of 640 MET-minutes per week, which is why the review closes by recommending combined programs rather than either mode alone.
The mechanism section explains why exercise can help a liver that never sees a treadmill. Exercise-induced myokines, including one shown to suppress the hepatocyte cGAS-STING signaling pathway, reduce the inflammatory and cell-death machinery inside the liver, which is a weight-independent channel from muscle to hepatocyte that makes the training plan a liver intervention in its own right.
Practical translation is where the review goes from statistics to schedule. Brisk walking runs near 4 to 5 METs, jogging near 8, so 630 MET-minutes lands at roughly 130 to 150 minutes of brisk walking or 75 to 80 minutes of jogging a week, with two resistance sessions layered in, which fits inside the familiar 150-minute public health frame without demanding anything heroic.
What makes this analysis different from the dozens of exercise reviews that preceded it is the statistical architecture. A Bayesian network meta-analysis lets every trial borrow information from every other trial, so the comparison between modes that were never tested head to head still produces a ranking, and the dose-response arm adds the minimal-important-difference concept, which separates statistically significant from clinically meaningful.
The authors set the context with a prevalence number worth remembering: MASLD now affects roughly 38 percent of the global adult population, and hepatic steatosis is reversible, which makes it the widest intervention window in chronic liver disease. The review is essentially a manual for using that window, written in units a clinic can prescribe.
For a reader with fatty liver, the 630 target is the practical headline. A 30-minute brisk walk five days a week clears it, or 40-minute walks four days a week with a single resistance session, and the plateau at 850 means the person doing two hours of daily cardio is past the point of diminishing liver returns and can spend that time on other health work.
The combined-training advantage has a muscle-protection side that matters for this site’s audience. Resistance work preserves lean mass during weight loss, and the MASLD population skews toward sarcopenia and frailty, so the 640 prescription is not just better for the liver, it is the version of exercise that keeps the body the liver lives in strong enough to keep training.
None of this argues that exercise replaces the plate. The weight-loss literature remains unambiguous that caloric deficit is the dominant driver of steatosis reduction, and this review’s own framing calls exercise the second rail, the one that preserves muscle, improves insulin sensitivity, and adds the weight-independent myokine channel while the diet does the heavy lifting.
The honest limits belong in the same paragraph as the strengths. Twenty-four trials and 961 people is a modest evidence base, the trials used different steatosis measurements, CAP, MRI-PDFF, ultrasound, and the MET thresholds are derived estimates rather than measured doses, so the 460-630-850 numbers are decision aids, not laws carved in stone.
For the newly diagnosed reader the sequence is simple. Stage the liver with a doctor first, confirm the steatosis and the metabolic picture, then pick the 630 target, start below it and build, and measure response the way the clinic already does, with the same elastography and ALT numbers the trials used, at the same three-to-six-month cadence.
The adherence reality deserves its own honest line. Trials are supervised, life is not, and the review’s own translational note concedes that the best prescription is the one the patient actually sustains, which is why the 630-versus-850 gap is useful: it tells people to stop chasing volume and start protecting consistency.
For a reader who has been told “just exercise more” for years, this analysis finally supplies the missing number. The liver-specific dose is 630 MET-minutes a week, combined training is the best mode, and the plateau at 850 means the goal is achievable, measurable, and finished, three properties a vague prescription never had.
The verification loop closes with the clinic, not the gym. Liver response to exercise shows up on the same instruments the trials used, elastography CAP, MRI-PDFF, and ALT, so the reader who logs 630 MET-minutes a week for three to six months and then repeats the test has turned a training schedule into a measurable liver intervention, which is the difference between exercising for general fitness and exercising for steatosis specifically.
The food side of the same equation is this site’s territory. Exercise improves insulin sensitivity and drives myokine signaling, but the liver still needs the diet rows to cooperate, and the practical week is the one that pairs the 630 MET-minutes with the friendly plate, fish, whole grains, vegetables, and water, because the review’s own dose-response curve was built on trials that counseled diet alongside training, not instead of it.
What are the three dose thresholds?
Across 24 randomized trials with 961 participants, the analysis put the minimum clinically effective dose at 460 MET-minutes per week, the cost-effective sweet spot at 630, and the plateau where added volume stops adding benefit at 850. Aerobic plus resistance training together hit the best value at 640 MET-minutes per week.
How do I translate MET-minutes into a weekly plan?
Brisk walking sits near 4 to 5 METs, jogging near 8, so 630 MET-minutes is roughly 130 to 150 minutes of brisk walking or 75 to 80 minutes of jogging, spread across the week. The resistance component lands at two sessions a week with the aerobic days between.
Does exercise work without weight loss?
The review found all exercise types lowered hepatic steatosis on their own, and the translation literature ties part of the effect to myokines that suppress the hepatocyte cGAS-STING pathway, which is a weight-independent channel. Weight loss remains the strongest lever, and exercise is the reliable second rail under it.